Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

New data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO) shows that more patients on Vabysmo had an absence of blood vessel leakage in ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

Credit: Shutterstock. Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...